Dave  Helsel net worth and biography

Dave Helsel Biography and Net Worth

David D. Helsel currently serves as Senior Vice President of Global Operations and R&D and has been with AngioDynamics since December 2017.Prior to joining AngioDynamics he was Senior Vice President, Global Supply Chain, at Hill-Rom Holdings for almost three years.  Before that, Mr. Helsel worked at Haemontiecs for three years where he served as Executive Vice President for Global Manufacturing and also spent almost nineteen years in various positions with increasing responsibility at Covidien, including Vice President of Operations for the Surgical Solutions Division and Medical Supplies Division.  An expert in Lean and Six Sigma, Mr. Helsel also served as Global Director of Operational Excellence, supporting sixty-three manufacturing facilities.Mr. Helsel holds a Bachelor of Science in Mechanical Engineering from LeTourneau University.

What is Dave Helsel's net worth?

The estimated net worth of Dave Helsel is at least $129,333.86 as of January 31st, 2023. Mr. Helsel owns 19,189 shares of AngioDynamics stock worth more than $129,334 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Helsel may own. Learn More about Dave Helsel's net worth.

How do I contact Dave Helsel?

The corporate mailing address for Mr. Helsel and other AngioDynamics executives is 14 PLAZA DRIVE, LATHAM NY, 12110. AngioDynamics can also be reached via phone at (518) 795-1400 and via email at [email protected]. Learn More on Dave Helsel's contact information.

Has Dave Helsel been buying or selling shares of AngioDynamics?

Dave Helsel has not been actively trading shares of AngioDynamics during the last quarter. Most recently, Dave Helsel sold 4,633 shares of the business's stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $12.95, for a transaction totalling $59,997.35. Following the completion of the sale, the senior vice president now directly owns 19,189 shares of the company's stock, valued at $248,497.55. Learn More on Dave Helsel's trading history.

Who are AngioDynamics' active insiders?

AngioDynamics' insider roster includes Chad Campbell (SVP), Scott Centea (VP), James Clemmer (CEO), James Clemmer (CEO), Dave Helsel (SVP), and Stephen Trowbridge (CFO). Learn More on AngioDynamics' active insiders.

Are insiders buying or selling shares of AngioDynamics?

During the last twelve months, AngioDynamics insiders bought shares 5 times. They purchased a total of 32,568 shares worth more than $202,847.12. The most recent insider tranaction occured on October, 10th when SVP Warren Nighan Jr bought 100 shares worth more than $608.00. Insiders at AngioDynamics own 5.4% of the company. Learn More about insider trades at AngioDynamics.

Information on this page was last updated on 10/10/2024.

Dave Helsel Insider Trading History at AngioDynamics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2023Sell4,633$12.95$59,997.3519,189View SEC Filing Icon  
7/29/2022Sell5,000$22.44$112,200.0023,822View SEC Filing Icon  
4/28/2022Sell3,513$22.44$78,831.7222,874View SEC Filing Icon  
10/20/2021Sell3,494$27.97$97,727.18View SEC Filing Icon  
4/14/2021Sell3,500$23.93$83,755.0019,115View SEC Filing Icon  
See Full Table

Dave Helsel Buying and Selling Activity at AngioDynamics

This chart shows Dave Helsel's buying and selling at AngioDynamics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AngioDynamics Company Overview

AngioDynamics logo
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Read More

Today's Range

Now: $6.74
Low: $6.69
High: $6.88

50 Day Range

MA: $6.98
Low: $5.88
High: $7.78

2 Week Range

Now: $6.74
Low: $5.26
High: $8.25

Volume

500,986 shs

Average Volume

527,276 shs

Market Capitalization

$273.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67